Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition by unknown
ANCHOR SEQUENCE-DEPENDENT ENDOGENOUS
PROCESSING OF HUMAN IMMUNODEFICIENCY
VIRUS 1 ENVELOPE GLYCOPROTEIN gp160
FOR CD4+ T CELL RECOGNITION
BY MICHAEL POLYDEFKIS,' SCOTT KOENIG,§ CHARLES FLEXNER,$
EUGENE OBAH,' KELLY GEBO,' SEKHAR CHAKRABARTI,1
PATRICIA L . EARL,n BERNARD MOSS,M AND ROBERT F SILICIANO'
From the Departments of 'Medicine and ZPharmacology, TheJohns Hopkins University School of
Medicine, Baltimore, Maryland 21205; and the §Laboratory of Immunoregulation and the
IILaboratosy of Viral Diseases, National Institutes of Allergy and Infectious Diseases,
National Institutes of Health, Bethesda, Maryland 20892
The recognition of protein antigens by CD4+ and CD8+ T cells requires a crit-
ical initial step in which the antigen is denatured and/or partiallyproteolyzedwithin
the APC. Two major pathways for the processing of protein antigens have been
identified (1-12). Exogenous antigens taken up from the extracellular environment
by macrophages and otherAPC are processed in alow pH endocytic compartment
(1-4) . Fragments ofprocessed antigen then associate with class IIMHC gene prod-
ucts, and the resulting complexes are expressed on the cell surface for subsequent
recognition by CD4+ T cells (13-15) . In contrast, antigenic proteins that are syn-
thesized within APC (as in the case of viral infection) are generally processed for
association with class I MHC gene products and subsequent recognition by CD8+
Tcells (4-12) . Theprocessing ofthese endogenous antigens forassociationwith class
IMHC molecules appears to require that theproteinbe synthesized within or other-
wise gain access to the cytoplasm of the cell (5-12) .
Viral envelope proteins present an interesting problem in terms of antigen pro-
cessing because these proteins are translocated during biosynthesis into the lumen
of the rough endoplasmic reticulum (RER).t Class I-restricted T cell responses to
viral envelope proteins synthesized in infected cells have been observed foranumber
of viruses, including influenza (7), and are particularly prominent in the case of
infection by the human immunodeficiency virustype 1 (HIV1) . HIV-1-infected in-
dividuals have high levels of circulating CD8 + CTL specific for the HIV -1 envelope
glycoprotein gp160 (16-19) . Interestingly, class II-restricted T cell responses to the
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envelope proteins of influenza virus have also been observed (7, 20, 21). However,
in some instances this appears to result from the uptake ofexogenous, virion-associated
envelope protein and subsequent processing by the normal class II pathway rather
than the direct processing within the infected cellsof endogenously synthesized enve-
lope protein (7, 21). It is therefore unclear whether endogenously synthesized viral
envelope proteins can generally be processed within infected cells for association
with class II MHC gene products and subsequent recognition by CD4+ T cells.
We present here a mechanistic analysis ofthe processing of the envelope glycopro-
tein gp160 ofHIV-1 and show that endogenously synthesized gp160 can be processed
for recognition by CD4+ T cells. This processing requires that the protein, after
synthesis on the RER and during subsequent cellular transport, remain attached
to the luminal/extracellular membrane face by a hydrophobic anchor sequence.
Materials and Methods
Antigens.
￿
Recombinant HIV-1 gp120 produced in Chinese hamster ovary (CHO) cells
transfected with a truncated form of the gene encoding the gp160 envelope precursor protein
as previously described (22) was kindly provided by Drs. Tim Gregory and Phil Berman
of Genentech, Inc. (South San Francisco, CA). Recombinant HIV-1 gp160 produced using
the baculovirus expression system was kindly provided by Dr. Gale Smith, MicroGeneSys,
Inc., New Haven, CT. A synthetic peptide representing amino acids 410-429 of gp160 of
the PV22 strain ofHIV-1 (GSDTITLPCRIKQFINMWE) was produced using standard solid-
phase methods and was purified by reverse-phase HPLC as previously described (23).
TCell Linesand Clones.
￿
The HIV-1 gp120-specific CD4' human T cell clone Een217 was
isolated from an HIV-1 seronegative donor as previously described (23). The CD4' T cell
clone ERT5.3 was derived from the same donor by limiting dilution cloning of PHA-activated
PBMC. The gp160-specific CD8' human T cell clone SFIE91 was isolated from an HIV-1
seropositive donor as previously described (18). The gp160-specific human T cell line 15.2
was derived from avolunteer who received a recombinant gp160 subunit vaccine (MicroGene-
Sys, Inc.) as part of a Phase I AIDS vaccine trial conducted by theJohns Hopkins University
Center for Immunization Research. All T cell clones and lines were maintained in the pres-
ence of IL-2 with weekly restimulation with irradiated PBMC and antigen or mitogen.
Vaccinia Virus Vectors.
￿
The vPE7 vector for the expression of HIV-1 env gene has been de-
scribed (24, 25). Higher levels of env gene expression were achieved using a related vector,
vPE16, in which two vaccinia early transcriptional termination signals in the env sequence
were eliminated by changes at the nucleotide level (Earl, P. L., and B. Moss, manuscript
submitted for publication). The vPE8 vector was prepared by deleting the gp41 sequence
and inserting a stop codon at the end of the gp120 coding sequence just 5' of the proteolytic
processing signal sequence (REKR) at which gp160 is cleaved into gp120 and gp41 (Earl,
P. L., and B. Moss, manuscriptin preparation). To eliminate the signal peptide from gp160,
a plasmid carrying the env gene, mpPE7 (25), was mutagenized at the junction ofthe signal
peptide and gp160 with the oligonucleotide ATCTGTAGTGCTGATATCCACCATGACAG-
AAAAATTG, adding an Eco RV site and an ATG codon. The 2.4-kb Eco RV fragment con-
taining the gene was cloned into the Sma I site of pSC11 (24) to generate pPEll . To express
the gp120 sequence attached to a vesicular stomatitisvirus (VSV) G protein anchor sequence,
the plasmid mpSCenv (24) was used as the parent of mpenvVSV. It was mutagenized at the
3' end ofgp120 witholigonucleotide GAGAGAAAACCCGGGAAGAGCAGT to insert a Sma I
site. This clone was cut with Sma I and Xho I to remove the gp41 coding sequence. A 250-bp
Alu I-Xho I fragment from pMM37 (26) containing the VSVG anchor sequence was then
inserted into the Sma I-Xho I cut mpSCenv mutant. The clone, mpenvVSV, contains a hy-
brid gene between HIV-1 gp120 and the VSVG anchor. The coding region was removed
with Sph I and Sst 1, blunted with T4 polymerase, and inserted into the Sma I site of PSCll
to make the plasmid pSC38. The recombinant viruses vPEll and VSC38 were made by ho-
mologous recombination between wild-type vaccinia and the plasmids pPEll and pSC38,POLYDEFKIS ET AL.
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respectively, by standard techniques (27). The preparation of the vPE12 vector in which the
proteolytic processing site has been deleted will be described elsewhere (Earl, P L., and B.
Moss, manuscript submitted). Viruses were grown in HeLa cellsand purified by centrifuga-
tion through a 36% sucrose cushion and then by rate zonal centrifugation through a 25-40%
sucrose gradient. vPE16 was obtained from the AIDS Research and Reference Reagent Pro-
gram, NIH, Bethesda, MD.
Cytolytic Assays.
￿
Cytotoxicity was measured in a S'Cr-release assay as previously described
(23) except that the assay period was 8 h. Target cells were pulsed with the indicated antigens
or infected with recombinant vaccinia viruses for 12-16 h at 37°C before labeling with "Cr
and use in the cytolytic assay. Vaccinia infection oftarget cells was carried out at a multiplicity
of infection (MOI) of 10. UV light inactivation was performed using a Blak Ray UV light
at 6 cm for 15 min on ice.
Western Blots.
￿
Laz 509 cells were infected with each virus (MOI = 10) for 18 h at 37oC.
Cells were washed three times, lysed in SDS sample buffer, and electrophoresed on 8°Io SDS-
polyacrylamide gels. Supernatants from infectionswere precipitated with trichloroacetic acid,
and precipitates were also electrophoresed. Proteins were transferred onto nitrocellulose and
detected with a rabbit anti-gp160 antisera (generous gift of Dr. Ron Willey, National Insti-
tutes of Health, Bethesda, MD) and "'I-labeled Protein A (Pharmacia Fine Chemicals, Pis-
cataway, NJ).
Results
ProcessingofEndogenously Synthesizedgp160.
￿
To investigate the mechanisms by which
viral envelope proteins are processed for recognition by CD4+ T cells, we exam-
ined human T cell recognition of the HIV-1 envelope glycoprotein gp160. This pro-
tein is synthesized on the RER of the infected cell and is cleaved by a cellular pro-
tease into a larger NH2-terminal glycoprotein (gpl20), which remains noncovalently
associated with the smaller membrane-spanning COOH-terminal fragment (gp41)
(28-31). CD4+ human T cell clones specific for gpl20 were isolated by stimulation
ofperipheral blood T cellsfrom HIV-1 seronegative donors with soluble recombinant
gpl20 and autologous monocytes followed by soft agar cloning (23). The representa-
tive CD4+ gpl20-specific T cell clone used in these studies, Een217, recognized an
epitope in gpl20 (residues 410-429) in association with HLA DR4 (DwlO) (23). This
clone showed a high level of antigen-specific cytolytic activity against autologous
macrophages and B lymphoblastoid cells that had taken up and processed exoge-
nous gpl20 (23).
To determine whether Een217 also recognized endogenously synthesized enve-
lope protein, we used recombinant vaccinia vectors to express the HIV-1 ena gene
within cells ofan autologous EBVtransformed B lymphoblastoid cell line (Laz 509).
As shown in Fig. 1 A, Een217 lysed autologous B lymphoblastoid cellsthat had been
pulsed with exogenous gpl60 or with a peptide representing the epitope in gpl60
that is recognized by this clone (residues 410-429). Significantly, Een217 also showed
a high degree of lytic activity against target cells infected with a recombinant vac-
cinia vector carrying the HIV-1 ena gene (vPE16). In contrast, there was little lysis
oftarget cellsinfected with a similar vaccinia vector lacking the HIV-1 ena gene (vSC8).
The lysis of vPE16-infected cells was not due to the uptake and processing of trace
amounts of exogenous gpl60 or gpl20 associated with the sucrose gradient-purified
recombinant virus preparation. Rather, as shown in Fig. 1 B, infectious virus was
required since virus preparations inactivated with UV light did not efficiently render
Laz 509 cells susceptible to lysis, whereas similarly treated intact gpl60 protein was
highly effective. Taken together, these results demonstrate that, when synthesized878
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Recognition of endogenously synthe-
sized gp160/120 by the CD4' T cell clone
Een217. (A) Lysis of the autologous EBV
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Lysisby Een217 was measured asdescribedabove.
in infected cells, the HIV-1 envelope protein gp160 can be processed for association
with class II MHC gene products and subsequent recognition by CD4' T cells.
Several mechanisms for the processing ofendogenously synthesized gp160 were
considered. One possibility is that gp120/gp41 complexes expressed on the surface
ofinfected cells undergo dissociation releasing soluble gp120, which is subsequently
taken up nonspecifically by cells and processed by the normal class II pathway. An-
otherpossibility is that processing takes place after endocytic uptake ofmembrane
gp120/gp41 complexes expressed on the surface of infected cells. Alternatively, the
delivery ofthe envelope protein to compartments where processing and MHC as-
sociation take place could occur by a completely intracellular route. It is also pos-
sible that cytoplasmic degradation of a small amount of newly synthesized gp160
that is not translocated into the lumen ofthe RER could generate the peptide frag-
ments that ultimately associate with class II MHC molecules.
Expression ofAlteredFormsoftheHIV1 env Gene.
￿
To distinguish among these alter-
natives, we used a series ofvaccinia constructswith various alterations in the HIV-1
env gene (Figs. 2 and 3). The vPE16 and vPE7 vectors contain the entire ena gene
and express gp160, which is cleaved to give gp120 and gp41. The vPE11 vector has
been modified to remove the NH2-terminal hydrophobic leader sequence of the
envelope protein. This vector directs the synthesis ofa form ofgp160 that is rapidly
degraded in the cytoplasm. Although gp160 expression by cells infected with vPEll
was not readily detectable by Western blotting analysis (Fig. 3), expression was de-
tected by immunofluorescence analysis ofpermeabilized cells. In addition, target
cells infected with vPE11 were readily lysed by class I-restricted CTL (see below).FIGURE 2 . Vaccinia vectors
for the expression of the HIV -1
envgene. Portions ofthe esw gene
inserted into the recombinant
vaccinia expression system (27)
are shown . Hydrophobic re-
gions in the env sequence in-
cluding the NH2-terminal
leader sequence (L) of gp160
and the fusion (F) and trans-
membrane (T)anchor domains
ofgp41 are boxed . The proteo-
lytic processing sites at which
the signal peptide is cleavedand
at which the gpl60 is cleaved to
gpl20and gp41 are indicatedby
arrows. The position ofthe epi-
tope (E) in gp120 recognized by
Een217 (residues 410-429) is
also indicated . The vPE16and
vPE7 vectors contain the entire
HIV -1 env gene (BH8 clone),
starting at the putative transla-
tion initiation codon, under the
control ofa vaccinia virus pro-
moter as previously described
(24). ThevPE16 vectorhas been
modified by site-directed muta
genesis to remove two vaccinia early termination signal sequences present within the env gene . This
alteration results in significantly greater env gene expression. In the vPE1l vector, the leader sequence
ofthe envgene hasbeen eliminated and a Metcodonhasbeen placed immediately 5' of the first residues
of the mature protein (TEK . . . ). In the vPE8 vector, the gp41 coding sequence has been removed
and a stop codon has been placed at the end of the gpl20 coding sequence just 5' of the proteolytic
processing signal sequence (REKR), which directs the cleavage of gpl60 into gpl20 and gp41. In the
vPE12 vector, the processing site has been removed . See Materials and Methods for details of vector
construction .
FIGURE 3 .
￿
Expression of wild-type and mutant HIV -1 env genes in Laz 509 target cells . The
expression ofgpl60andgp120 was detected by Western blot analysis ofcell lysates (C)and super-
natants (S) after infection with recombinant vaccinia viruses.
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The vPE8 vector lacks the gp41 coding sequence and has a stop codon within the
env gene the near the gp120/gp41 proteolytic processing site. As shown by Western
blot analysis(Fig. 3), this vector induced the production oflarge amounts ofgp120,
which was detected in infected cells and which was secreted into the medium. In
the vPE12 vector, the env gene has been modified to remove codons for 12 residues
(KRRVVQREKRAV) at the COON terminus ofgp120, including the proteolytic
processing site at which gp160 is normally cleaved into gp120 and gp41. As shown
in Fig. 3, this vector directed the synthesis ofa gp160 protein that was not cleaved
into gp120 and gp41. Consistent with the modifications described above, analysis
of cell surface expression of gp160/120 by flow cytometry was positive on cells in-
fected with vPE7, vPE16, and vPE12 but negative on cells infected with vPEll and
vPE8 (data not shown) .
EBVtransformed B lymphoblastoid cellsofappropriate MHC genotype were in-
fected withthese recombinantviruses and tested forsusceptibility tolysisbyenvelope-
specific CTL. Inallexperiments, cellsinfectedwith thevaccinia recombinantVSC8,
which lacks the HIV-1 env gene, were used as negative controls. Cells infected with
vPE7 or vPE16, which express the wild-type env gene, served as positive controls.
Processing ofSignal Peptide-minusEnvelopeProtein.
￿
Todetermine whethertransloca-
tion of the newly synthesized envelope protein into the RER was required for pro-
cessing, the signal peptide-minus vector vPEll was used. As shown in Fig. 4, the
lysis ofvPE11-infected Laz 509 cells by the CD4+ CTL clone Een217 was very weak
compared with the lysis ofvPE16-infected cells that express the wild-type envelope
protein. In contrast, vPEll-infected B lymphoblastoid cells were readily lysed by
a gp160-specific, MHC class I-restricted CD8' CTL clone (Fig. 5). These results
suggested that gp160 synthesized in the cytoplasm ofan infected cell was efficiently
processed for class I-restricted, but not class II-restricted recognition. This may
reflect the fact that insufficient amounts ofthe protein accumulated for class II-re-
stricted processing. Alternatively, efficient processing for association with class II
MHC molecules may require that the protein be translocated during synthesis into
the RER, asindicated bythehigher levels oflysis ofvPE16-infected cellsby Een217 .
Processing ofAnchor Sequence-minus Envelope Protein.
￿
Although translocation ofthe
newlyenvelope synthesized proteininto theRER appearedto be necessary forefficient
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FIGURE 4.
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Lysis of target cells ex-
pressing signal peptide-minus gp160
by a CD4' CTL clone. Laz 509 cells
were infected with the signal pep-
tide-minus recombinant vaccinia virus
vector vPE11 or thepositive andnega-
tive control vectors vPE16 and vSC8,
respectively. Lysisby cloneEen217 was
measured in an 8-h S'Cr-release assay.y
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FIGURE 5. Lysis of target cells ex-
pressing signal peptide-minus gpl60
by a CD8' CTL clone. Autologous
EBVtransformed B lymphoblastoid
cells were infected with vPE11, vPEl6,
or vSC8. Lysis by the CD8' CTL
clone SFIE91 was measured in a 4-h
"Cr-release assay.
class 11-restricted processing, translocation was not a sufficient condition for class
II-restrictedprocessing since cells infected with thevPE8 vector, which induced the
production of an anchor sequence-minus, secreted form of gp120, were not lysed
(Fig. 6 A). The gp120 protein produced by vPE8-infected cells contains the epitope
recognized by Een217 (Fig. 2). The failure of Een217 to lyse vPE8-infected cells was
particularly noteworthy in light of the fact that vPE8-infected cells produced alarge
amount of envelope protein compared with cells infected with the wild-type vector
vPE7 (Fig. 3) . Even cells infected with vPE8 at very high multiplicities (30:1) were
not lysed. As shown in Fig. 6 B, these results were not unique to clone Een217 since
the gp160-specific CD4+ T cell line 15.2, which was obtained from a different donor
and which recognized epitopes within gpl20, also recognized endogenously synthe-
sized gp160 when the protein was synthesized normally (vPE16), but not when it
was made as a secreted protein (vPE8).
Two important conclusions can be drawn from these experiments. First, lysis of
cells expressing the normal HIV-1 env gene by CD4+ CTL was not simply due en-
docyticuptake and processing theexogenous envelope protein released by othercells.
There was no lysis of vPE8-infected B lymphoblastoid cells that released into the
supernatant a much larger amount of gp120 than did vPE16- or vPE7-infected cells
(Fig. 3). These results argue strongly that endogenously synthesized envelope pro-
tein is processeddirectly for classII-restricted recognition at a single cell levelwithout
a requirement forrelease into the fluid phase and subsequent endocytic uptake and
processing. Second, the results indicate that transportofsignificant amounts ofenvelope
protein into the RER is not sufficient for processing. Rather, it appears that pro-
cessing ofendogenously synthesized gp160 for class II-restricted recognition requires
that after synthesis on the RER and during subsequent intracellulartrafficking, the
protein remain attached to the luminal/extracellular membrane face by a hydro-
phobic anchor sequence.
Processing ofMembrane-anchoredFormsoftheEnvelope Protein.
￿
To test this hypothesis,
we used two other recombinant vaccinia vectors that directed the synthesis offorms
of the envelope protein that remained anchored to the luminal/extracellular mem-
brane face by a hydrophobic anchor sequence. In cells infected with vPE12, gp160
is not cleaved into gp120 and gp41 as a result of deletion of the proteolytic cleavage882
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￿
Lysis of target cells
expressing anchor-sequence
minus envelope protein by
CD4' CTL clones and cell
lines. (A)Laz509cells were in-
fected with the anchor sequence-
minus recombinant vaccinia
virus vector vPE8 or the posi-
tive control vectors vPE7 and
vPE16, or the negative control
vector vSC8. Lysis by clone
Een217 was measured in an 8-
h 5'Cr-release assay. (B) Autol-
ogous EBVtransformed B lym-
phoblastoid cells were infected
with vPE8, vPE16, or vSC8.
Lysis by the CD4' CTL line
15.2 was measured in an 8-h
"Cr-release assay.
signal sequence (REKR). Therefore, gp120 cannot dissociate from the transmem-
branegp41 protein and remains membrane associated. As shownin Fig. 7 A, vPE12-
infected cells were readily lysed, indicating that cleavage of gp160 into gp120 and
gp41 was not required for antigen processing. The vSC38 vector, in which the NH2-
terminal portion of the env gene including the gp120 coding sequence was fused to
the membrane anchor and COOH-terminal cytoplasmic domain of the vesicular
stomatitis virus glycoprotein G, directs the synthesis of a fusion protein which is
expressed on the surface of infected cells as shownby flow cytometry (Chakrabarti,
S., and B. Moss, unpublished results). Cells infected with VSC38 were lysed to the
same extent as cells infected with the vPE7 vector that expresses the unaltered env
gene (Fig. 7B). These results demonstratethat it is the presence of a membrane an-
chor sequence and not the nature of the anchor sequence that allows endogenously
synthesized envelope proteinto be processed for class II-restricted antigen recognition.
Discussion
In this study, we examined whether endogenously synthesized HIV-1 envelope
glycoproteins could be processed for association with class 11 MHC gene productsJ
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FIGURE 7.
￿
Lysis of target cells
expressingmembrane-anchored
formsofthe HIV-1 envelope gly-
coprotein by the CD4+ CTL
clone Een217. (A) Laz 509 cells
were infected with the gp120/
gp41 cleavage site- minus re-
combinant vacciniavirus vector
vPE12, thepositive control vec-
tor vPE16, or the negative con-
trol vector vSC8. Lysis by clone
Een217 was measured in an 8-h
5'Cr-release assay. (B) Laz 509
cells were infected with the
VSVG anchored gpl20 expres-
sion vector vSC38, the positive
control vector vPE16, or the
negative control vector vSC8.
Lysis by clone Een217 was mea-
sured in an 8-h "Cr-release
assay.
and subsequent recognition by CD4+ T cells. To detect such a processing event,
we used CD4+ T cell clones generated in response to soluble forms of the envelope
glycoprotein. These clones recognized exogenous gp160 that hadbeen taken up and
processed by APC. To determine whether endogenously synthesized gp160 could
alsobe processed forrecognitionby theseclones, weused recombinant vaccinia virus
vectors to express the HIV-1 env gene in autologous B lymphoblastoid cells. Our
data demonstrate that in this system, endogenously synthesized gp160 is processed
for class II-restricted recognition by at least some CD4+, gp160-specific T cell
clones. Lysis ofcellsexpressing the env generesults from theprocessing ofendogenously
synthesized envelope protein rather than processing ofexogenous envelope protein
takenup bytarget cells. This was demonstrated by showingthat vPE8-infected cells
thatreleaselargeamounts ofa solubleformoftheenvelopeprotein into themedium
were not themselves lysed. Rather, processing requires that the protein remain cell
associated. It should be pointed out that B lymphoblastoid cells can take up and
process soluble exogenous gp120, but only when the protein is present at a concen-
tration (10-7 M), which greatly exceeds the concentration of gp120 secreted by
vPE8-infected cells under these conditions. In contrast, activated CD4+ T cells can884
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take up and process very low amounts of gp120 (23), and these cells are lysed by
Een 217 after coculture withvPE8-infectedB lymphoblastoid cells (Siliciano, R. F,
unpublished results). Thus vPE8-infected cells produce a form ofthe envelope pro-
teinthat contains the epitope recognized by Een217, but do not directly processthe
protein. Incontrast, cells infectedwithvectors expressingmembrane-anchored forms
oftheenvelopeprotein did showprocessing forclass II-restrictedrecognition. These
results indicate anchoringofthe protein to theluminal/extracellular membrane face
isrequiredfor deliveryofthe gp160tothe appropriate cellular compartments where
processing takes place.
Several mechanisms could explain the anchor-sequence dependence of the pro-
cessing of gp160 for class II-restricted recognition. One possibility is that the pro-
cessing requires the expression ofthe gp120/41 complex on the plasma membrane
followedbyendocyticuptake ofthecomplex and subsequent processingby thenormal
class II pathway for processing of exogenous antigens. Such a model is consistent
with the findingthatleupeptin partiallyinhibits processingofboth exogenously added
and endogenously synthesized gp160 (data not shown). It is also possible that an
anchor sequence is required for the intracellular delivery of gp160 to the compart-
ments where processing and MHC association take place. In this regard, it is in-
teresting to note that Willey and colleagues have recently shown that only a small
fraction ofthe newly synthesized gp160 produced in HIV-1-infected cells is cleaved
to gp120 and gp41, and thatthe uncleaved gp160 is sorted to lysosomes fordegrada-
tion (31).
It is of interest to consider these findings in light of results obtained with other
viral proteins that are processed for class II-restricted recognition. In contrast to
the results described above, classII-restrictedrecognition ofthe hemagglutinin (HA)
of influenza appears to involve uptake from the extracellular fluid of HA present
in the virus preparation (7) or released from cellsexpressing the HA gene (22). The
recognitionofthe influenzaneuraminidase bysome T cell clones appears to require
viral gene expression (21) and may occur by a mechanism similar to that used by
HIV-1 gp160. Class II-restricted recognition ofthe HSV type 1 glycoprotein D ex-
pressedin HSVinfectedor recombinant vacciniavirus-infected cellshasbeen reported
(32). Processing ofendogenously synthesized Igby Blymphoma cells has also been
described (33). The anchor-sequence dependence ofprocessing in these systems is
as yet unclear. Class II-restricted recognition ofendogenously synthesized measles
virus matrix and nucleocapsid proteins (34) and hepatitis B surface antigen (35)
also occurs, but the mechanism is likely to be different since these viral proteins
are not integral membrane proteins.
The results described here are of general interest for three reasons. First, they
demonstrate that endogenously synthesized viral envelope proteins can be directly
processed at the level of individual cells for class II-restricted as well as class I-re-
stricted recognition. Second, they provide insight into possible mechanisms for the
processingofviral envelope proteins forclass II-restricted reocognition. Finally, with
respect to AIDS vaccine development, our results indicate that CD4+ CTL induced
by immunization with purified envelope protein vaccines may be capable of des-
troying HIV-1-infected cells expressing processed envelope protein. Recent studies
indicate that these CTL can lyse HIV-1-infected autologous CD4` T cell clonesPOLYDEFKIS ET AL.
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(Siliciano, R. F., unpublished results). Thus, in addition to mediating potentially
detrimental effects through the destruction of noninfected, activated CD4+ T cells
that have taken up and processed free gp120 (23), such CTL may also serve to limit
the spread of HIV-1 infection by lysing infected macrophages and activated T cells.
Summary
Human CD4+ T cell clones and cell lines were shown to lyse recombinant vac-
cinia virus-infected cells that synthesize the HIV-1 envelope glycoprotein gp160. The
processing of endogenously synthesized gp160 for recognition by CD4+ T cells re-
quired that the protein, after synthesis on the rough endoplasmic reticulum and
during subsequent cellular transport, remain attached to the luminal/extracellular
membrane face by a hydrophobic anchor sequence.
We thank Drs. Tim Gregory and Phil Berman for providing recombinant gp120, Dr. Ron
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